ES2173891T3 - Sistema de liberacion pulsatil de un farmaco multiparticulado. - Google Patents

Sistema de liberacion pulsatil de un farmaco multiparticulado.

Info

Publication number
ES2173891T3
ES2173891T3 ES93916656T ES93916656T ES2173891T3 ES 2173891 T3 ES2173891 T3 ES 2173891T3 ES 93916656 T ES93916656 T ES 93916656T ES 93916656 T ES93916656 T ES 93916656T ES 2173891 T3 ES2173891 T3 ES 2173891T3
Authority
ES
Spain
Prior art keywords
balls
water
dosage form
index
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916656T
Other languages
English (en)
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2173891T3 publication Critical patent/ES2173891T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA FORMA DE DOSIFICACION DE UNIDAD DE CAPSULA (4) O TABLETA COMPUESTA DE UN GRAN NUMERO DE BOLITAS (6,7,5) QUE COMPRENDEN DOS O MAS POBLACIONES DE BOLITAS/PARTICULAS. CADA BOLITA CONTIENE UN NUCLEO (3) QUE CONTIENE EL MEDICAMENTO TERAPEUTICO Y UN AGENTE OSMOTICO SOLUBLE EN AGUA, QUE ENCIERRAN UN POLIMERO INSOLUBLE EN AGUA. EL RECUBRIMIENTO DE PELICULA DE CADA POBLACION DE BOLITAS DIFIERE DE RECUBRIMIENTO DE CADA UNA DE LAS OTRAS POBLACIONES DE BOLITAS EN LA FORMA DE DOSIFICACION EN EL INDICE AL QUE EL AGUA PASA AL NUCLEO, Y EL INDICE AL QUE LA MEDICINA SE DIFUNDE FUERA DEL NUCLEO. EL AGENTE OSMOTICO SE DISUELVE EN EL AGUA, CUASANDO QUE LA BOLITA SE HINCHE Y REGULANDO EL INDICE DE DIFUSION DEL MEDICAMENTO EN EL INTERVALO DE USO. MIENTRAS CADA POBLACION DE BOLITAS LIBERA SECUENCIALMENTE SUS MEDICAMENTOS EN EL INTERVALO, EL EFECTO ES PROPORCIONA UNA SERIE DE ADMINISTRACIONES PULSATILES DE MEDICAMENTO CON UNA SOLA FORMA DE DOSIFICACION.
ES93916656T 1992-05-04 1993-06-03 Sistema de liberacion pulsatil de un farmaco multiparticulado. Expired - Lifetime ES2173891T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/878,416 US5260068A (en) 1992-05-04 1992-05-04 Multiparticulate pulsatile drug delivery system
PCT/US1993/005922 WO1994028882A1 (en) 1992-05-04 1993-06-03 Multiparticulate pulsatile drug delivery system

Publications (1)

Publication Number Publication Date
ES2173891T3 true ES2173891T3 (es) 2002-11-01

Family

ID=25371983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916656T Expired - Lifetime ES2173891T3 (es) 1992-05-04 1993-06-03 Sistema de liberacion pulsatil de un farmaco multiparticulado.

Country Status (9)

Country Link
US (2) US5260068A (es)
EP (1) EP0701437B1 (es)
JP (1) JP3877329B2 (es)
AT (1) ATE215818T1 (es)
AU (1) AU680620B2 (es)
CA (1) CA2163433C (es)
DE (1) DE69331806T2 (es)
ES (1) ES2173891T3 (es)
WO (1) WO1994028882A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372225B2 (en) 2005-11-18 2013-02-12 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly
US8858960B2 (en) 2004-11-19 2014-10-14 GlaxoSmithKline, LLC Method of producing a pharmaceutical product

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
TW235239B (es) * 1992-11-20 1994-12-01 Pfizer
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5921285A (en) * 1995-09-28 1999-07-13 Fiberspar Spoolable Products, Inc. Composite spoolable tube
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
CA2275604A1 (en) * 1997-01-03 1998-07-09 Kenneth Iain Cumming Sustained release cisapride mini-tablet formulation
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
AU4679999A (en) * 1998-06-11 1999-12-30 Em Industries, Inc. Micro-osmotic controlled drug delivery systems
KR100630943B1 (ko) * 1998-06-12 2006-10-04 코닌클리케 필립스 일렉트로닉스 엔.브이. 재생 버퍼를 경유한 압축 오디오 전송
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
WO2000009092A1 (en) * 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
CN1406126A (zh) * 1998-10-01 2003-03-26 诺瓦提斯公司 新型缓释口服制剂
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
PT1251832E (pt) * 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
AU3986901A (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
AU3984101A (en) 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
CA2400784C (en) * 2000-02-24 2009-05-19 Advanced Pharma, Inc. Therapeutic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1341476A2 (en) * 2000-12-01 2003-09-10 Nephros Therapeutics, Inc. Intrasvascular drug delivery device and use therefor
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
US20070087048A1 (en) * 2001-05-31 2007-04-19 Abrams Andrew L Oral dosage combination pharmaceutical packaging
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
CA2447984A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
DE10214002A1 (de) * 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
SE0201110D0 (sv) * 2002-04-12 2002-04-12 Astrazeneca Ab New film coating
US20030203027A1 (en) * 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1613333A1 (en) * 2003-04-04 2006-01-11 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
ATE419841T1 (de) * 2003-09-03 2009-01-15 Pharmaton Sa Kapseln enthaltend wirkstoffpellets mit unterschiedlichen freisetzungsprofilen
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20090304793A1 (en) * 2003-09-22 2009-12-10 Alpharma, Inc. Sustained release opioid formulations and methods of use
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP5258297B2 (ja) * 2004-11-19 2013-08-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 個人別に療法を合わせるために可変用量の薬物併用製品を特注で調剤する方法
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
JP2008535922A (ja) * 2005-04-12 2008-09-04 エラン・ファルマ・インターナショナル・リミテッド 細菌感染を治療するためのセファロスポリンを含む放出制御組成物
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CN101316602B (zh) 2005-09-27 2015-06-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
ZA200804086B (en) * 2005-10-14 2009-07-29 Lundbeck & Co As H Stable pharmaceutical formulations containing escitalo-pram and bupropion
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1989144A4 (en) 2006-02-02 2014-01-29 Innovative Bio Therapies EXTRACORPOREAL THERAPEUTIC DEVICE AND DELIVERY SYSTEM BASED ON CELLS
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20070218126A1 (en) * 2006-03-16 2007-09-20 Tamer Laboratories, Inc. Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20070243245A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations, Methods of Preparing the Same, and Methods of Reducing Food Effects on Drug Release
WO2007123883A2 (en) * 2006-04-17 2007-11-01 Actavis Group Ptc Ehf Oral dosage formulations and methods of preparing the same
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2056818B1 (en) 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
EP2097067A2 (en) * 2006-12-05 2009-09-09 University Of The Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102171332A (zh) 2008-06-18 2011-08-31 创新生物制剂疗法公司 促进肾前体细胞增殖的方法
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
RU2519715C2 (ru) * 2008-10-23 2014-06-20 Хенкель Корпорейшн Фармацевтические гранулы, содержащие модифицированный крахмал, и их терапевтические применения
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
WO2010103367A1 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Pulsatile release composition of therapeutic agent
BRPI1010511A2 (pt) * 2009-04-09 2019-04-09 Alkermes Pharma Ireland Limited composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiva
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
ES2702753T3 (es) 2010-01-05 2019-03-05 Microdose Therapeutx Inc Dispositivo de inhalación
US8475846B2 (en) * 2010-03-09 2013-07-02 Basf Corporation Colored micaceous pigments having bismuth oxychloride appearance and performance effects
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
ES2688072T3 (es) 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt) 2011-03-23 2022-01-11 Ironshore Pharmaceuticals & Development, Inc Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2586429A1 (en) 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2620162A1 (de) 2012-01-27 2013-07-31 Life Science Inkubator Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation
CN104136004B (zh) 2012-02-22 2018-03-06 达切斯内公司 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
AU2013302657B2 (en) 2012-08-15 2018-08-09 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2014052914A1 (en) 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
ES2670619T3 (es) 2013-07-22 2018-05-31 Duchesnay Inc. Composición para la gestión de náuseas y vómitos
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3077388A1 (en) 2013-12-05 2016-10-12 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10399994B2 (en) 2015-02-06 2019-09-03 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
KR102629269B1 (ko) 2015-02-27 2024-01-24 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
TWI720984B (zh) 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
KR102605329B1 (ko) 2016-08-26 2023-11-22 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022515528A (ja) * 2018-12-28 2022-02-18 パンダ コンサルティング エルエルシー 短時間作用型選択的糖質コルチコイド受容体モジュレーター
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
AU2020240015B2 (en) 2019-03-15 2025-10-09 Unicycive Therapeutics Inc. Nicorandil derivatives
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
CN114828889B (zh) 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
CN113171351A (zh) * 2021-04-02 2021-07-27 海南锦瑞制药有限公司 一种盐酸地尔硫卓控释丸剂及其制备方法
CA3218884A1 (en) 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions
IL309073A (en) 2021-06-03 2024-02-01 Arcadia Medicine Inc Enantiomeric entactogen compounds and methods of their use.
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL311050A (en) 2021-08-23 2024-04-01 Alexander Shulgin Res Institute Inc Deuterated empathogens
EP4392027A4 (en) 2021-08-23 2025-07-23 Alexander Shulgin Res Institute Inc FLUORINATED EMPATHOGENS
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023034184A1 (en) 2021-08-31 2023-03-09 Cerespir Incorporated Co-crystals
IL311211B1 (en) 2021-09-03 2026-02-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
US12465578B2 (en) 2021-09-25 2025-11-11 Alexander Shulgin Research Institute, Inc. Substituted alpha-ethyl phenylalkylamines
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
CA3242316A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CA3249142A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE
EP4479404A1 (en) 2022-02-16 2024-12-25 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025072556A1 (en) 2023-09-26 2025-04-03 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives
WO2025208111A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL52914C (es) * 1937-11-24
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3684446D1 (de) * 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US5336504A (en) * 1987-10-16 1994-08-09 Elan Corporation, Plc Diltiazem formulations and methods of treatment
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858960B2 (en) 2004-11-19 2014-10-14 GlaxoSmithKline, LLC Method of producing a pharmaceutical product
US8372225B2 (en) 2005-11-18 2013-02-12 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly
US9187192B2 (en) 2005-11-18 2015-11-17 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly

Also Published As

Publication number Publication date
WO1994028882A1 (en) 1994-12-22
CA2163433C (en) 2003-07-08
US5508040A (en) 1996-04-16
ATE215818T1 (de) 2002-04-15
JPH09500866A (ja) 1997-01-28
US5260068A (en) 1993-11-09
EP0701437B1 (en) 2002-04-10
AU4643493A (en) 1995-01-03
JP3877329B2 (ja) 2007-02-07
EP0701437A1 (en) 1996-03-20
AU680620B2 (en) 1997-08-07
CA2163433A1 (en) 1994-12-22
DE69331806D1 (de) 2002-05-16
EP0701437A4 (en) 1996-10-09
DE69331806T2 (de) 2003-01-16

Similar Documents

Publication Publication Date Title
CA2163433A1 (en) Multiparticulate pulsatile drug delivery system
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
NO923590L (no) Doseringsform for avgivelse av medikament til tarmen
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
NO923756L (no) Osmotisk doseringssystem for avgivelse av vaeskeformig medikament
ATE30380T1 (de) Pharmazeutische formulierungen mit mehrfachen einheiten.
DE69330910D1 (de) Arzneiabgabesystem mit stossweiser freisetzung von partikeln
UY25710A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
MX166703B (es) Preparacion farmaceutica para liberacion sostenida
FR2395026A1 (fr) Dose medicamenteuse a unites multiples
ES2070837T3 (es) Nuevas formulaciones de liberacion controlada de compuestos de tetraciclina.
ATE65023T1 (de) Pharmazeutische mittel.
ES2157944T3 (es) Nucleos de pastillas de liberacion inmediata de medicamentos insolubles que poseen un recubrimiento de liberacion sostenida.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
ES2087281T3 (es) Sistema de produccion de fluidos de dialisis con pildora de dialisis.
GT198303076A (es) Formulaciones de pastillas de accion prolongada con disolucion paulatina.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ES275292U (es) Envase para suministrar productos farmaceuticos en forma seca.
MX169815B (es) Tableta de medicamento masticable que contiene medios para enmascarar el sabor
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
SE7711102L (sv) Nya medel och nya sett att behandla klimakteriska bortfallsymptom
NO933177D0 (no) Tablett for programmert avgivelse av naproksen
Smith et al. Hepatic failure following ingestion of multiple doses of acetaminophen in a young child
Anghileri et al. Antitumor activity of gallium and lanthanum: role of cation-cell membrane interaction

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701437

Country of ref document: ES